BACKGROUND: Post-operative atrial fibrillation (POAF) is common after aortic valve replacement (AVR) and is associated with worse outcomes. We performed a meta-analysis of randomized controlled trials comparing Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) for incidence of POAF at 30 days. METHODS: We searched databases from 1/1/1990 to 1/1/2020 for randomized studies comparing TAVR and SAVR. POAF was defined as either worsening or new-onset atrial fibrillation. Random effects model was used to estimate the risk of POAF with TAVR vs SAVR in all trials, and in subgroups (low, intermediate, high risk, and in self-expandable vs balloon expandable valves). Sensitivity analysis was performed including only studies reporting new-onset atrial fibrillation. RESULTS: Seven RCTs were identified that enrolled 7,934 patients (3,999 to TAVR and 3,935 to SAVR). The overall incidence of POAF was 9.7% after TAVR and 33.3% after SAVR. TAVR was associated with a lower risk of POAF compared with SAVR (OR 0.21 [0.18-0.24]; P < 0.0001). Compared with SAVR, TAVR was associated with a significantly lower risk of POAF in the high-risk cohort (OR 0.37 [0.27-0.49]; P < 0.0001), in the intermediate-risk cohort (OR 0.23 [0.19-0.28]; P < 0.0001), low-risk cohort (OR 0.13 [0.10-0.16]; P < 0.0001). Sensitivity analysis of 4 trials including only new-onset POAF showed similar summary estimates (OR 0.21, 95% CI [0.18-0.25]; P< 0.0001). CONCLUSIONS: TAVR is associated with a significantly lower risk of post-operative atrial fibrillation compared with SAVR in all strata. Further studies are needed to identify the contribution of post-operative atrial fibrillation to the differences in clinical outcomes after TAVR and SAVR.
BACKGROUND: Post-operative atrial fibrillation (POAF) is common after aortic valve replacement (AVR) and is associated with worse outcomes. We performed a meta-analysis of randomized controlled trials comparing Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) for incidence of POAF at 30 days. METHODS: We searched databases from 1/1/1990 to 1/1/2020 for randomized studies comparing TAVR and SAVR. POAF was defined as either worsening or new-onset atrial fibrillation. Random effects model was used to estimate the risk of POAF with TAVR vs SAVR in all trials, and in subgroups (low, intermediate, high risk, and in self-expandable vs balloon expandable valves). Sensitivity analysis was performed including only studies reporting new-onset atrial fibrillation. RESULTS: Seven RCTs were identified that enrolled 7,934 patients (3,999 to TAVR and 3,935 to SAVR). The overall incidence of POAF was 9.7% after TAVR and 33.3% after SAVR. TAVR was associated with a lower risk of POAF compared with SAVR (OR 0.21 [0.18-0.24]; P < 0.0001). Compared with SAVR, TAVR was associated with a significantly lower risk of POAF in the high-risk cohort (OR 0.37 [0.27-0.49]; P < 0.0001), in the intermediate-risk cohort (OR 0.23 [0.19-0.28]; P < 0.0001), low-risk cohort (OR 0.13 [0.10-0.16]; P < 0.0001). Sensitivity analysis of 4 trials including only new-onset POAF showed similar summary estimates (OR 0.21, 95% CI [0.18-0.25]; P< 0.0001). CONCLUSIONS: TAVR is associated with a significantly lower risk of post-operative atrial fibrillation compared with SAVR in all strata. Further studies are needed to identify the contribution of post-operative atrial fibrillation to the differences in clinical outcomes after TAVR and SAVR.
Authors: Shmuel Chen; Bjorn Redfors; Ori Ben-Yehuda; Aaron Crowley; Kevin L Greason; Maria C Alu; Matthew T Finn; Torsten P Vahl; Tamim Nazif; Vinod H Thourani; Rakesh M Suri; Lars Svensson; John G Webb; Susheel K Kodali; Martin B Leon Journal: JACC Cardiovasc Interv Date: 2018-08-28 Impact factor: 11.195
Authors: Rutger-Jan Nuis; Nicolas M Van Mieghem; Carl J Schultz; Adriaan Moelker; Robert M van der Boon; Robert Jan van Geuns; Aad van der Lugt; Patrick W Serruys; Josep Rodés-Cabau; Ron T van Domburg; Peter J Koudstaal; Peter P de Jaegere Journal: Am J Cardiol Date: 2012-03-15 Impact factor: 2.778
Authors: Jeffrey J Popma; G Michael Deeb; Steven J Yakubov; Mubashir Mumtaz; Hemal Gada; Daniel O'Hair; Tanvir Bajwa; John C Heiser; William Merhi; Neal S Kleiman; Judah Askew; Paul Sorajja; Joshua Rovin; Stanley J Chetcuti; David H Adams; Paul S Teirstein; George L Zorn; John K Forrest; Didier Tchétché; Jon Resar; Antony Walton; Nicolo Piazza; Basel Ramlawi; Newell Robinson; George Petrossian; Thomas G Gleason; Jae K Oh; Michael J Boulware; Hongyan Qiao; Andrew S Mugglin; Michael J Reardon Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Samir R Kapadia; Chetan P Huded; Susheel K Kodali; Lars G Svensson; E Murat Tuzcu; Suzanne J Baron; David J Cohen; D Craig Miller; Vinod H Thourani; Howard C Herrmann; Michael J Mack; Molly Szerlip; Raj R Makkar; John G Webb; Craig R Smith; Jeevanantham Rajeswaran; Eugene H Blackstone; Martin B Leon Journal: J Am Coll Cardiol Date: 2018-11-13 Impact factor: 24.094
Authors: David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Angelo B Biviano; Tamim Nazif; Jose Dizon; Hasan Garan; Jessica Fleitman; Dua Hassan; Samir Kapadia; Vasilis Babaliaros; Ke Xu; Rupa Parvataneni; Josep Rodes-Cabau; Wilson Y Szeto; William F Fearon; Danny Dvir; Todd Dewey; Mathew Williams; Michael J Mack; John G Webb; D Craig Miller; Craig R Smith; Martin B Leon; Susheel Kodali Journal: Circ Cardiovasc Interv Date: 2016-01 Impact factor: 6.546